Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD develops and commercializes carotid stent systems built around its MicroNet stent platform for carotid artery disease and stroke prevention. News for NSPR centers on CGuard Prime and CGuard product commercialization, U.S. and international demand, FDA interactions, IDE approvals, pivotal studies for TCAR-related use, and product quality actions such as the CGuard Prime 135 cm delivery-system recall.
Company updates also cover quarterly financial results, hospital adoption and procedure experience, publications from C-GUARDIANS studies, investor conference participation, and capital-market communications tied to its Nasdaq-listed common stock.
InspireMD, Inc. (NSPR) announced promising early results from the SIBERIA trial, presented during EuroPCR on June 25, 2020. This study compares the CGuard™ Embolic Prevention System to the Acculink™ stent for carotid artery revascularization in high-risk patients. Key findings include a 78% reduction in cerebral lesion volume with CGuard™ and zero new cerebral lesions at 30 days, contrasting with six lesions in the Acculink™ group (p=0.03). The trial highlights CGuard™'s potential to redefine standards in carotid stenting, aiming for safer, less invasive options.
InspireMD (NYSE American: NSPR) has priced a public offering of 22,222,200 units at $0.45 each, aiming to raise approximately $10.0 million. Each unit includes one share of common stock and one Series F warrant for $0.495 per share. The underwriter has a 45-day option to purchase an additional 3,333,333 units for up to $1.5 million. Funds will support research, development, marketing, and general corporate purposes. The offering is expected to close on June 5, 2020, pending customary conditions.
InspireMD reported a substantial revenue increase of 149.2% for Q1 2020, totaling $1,034,000, driven mainly by strong sales of the CGuard™ Embolic Prevention System (EPS), which rose 158.2% to $971,000. The company also noted a recovery from third-party sterilizer failures that impacted previous sales. Gross profit improved to $295,000 compared to a gross loss last year, with a gross margin of 28.5%. Despite a net loss of $1,978,000, cash reserves were reported at $3,141,000. InspireMD aims to expand its product offerings and market reach.